What is Lassogen?
Lassogen, Inc. is pioneering a novel class of programmable medicines derived from the optimization of lasso peptides, which they have branded as Lassotides. These therapeutics are engineered to bridge the gap between the high specificity of antibodies and the favorable pharmacokinetic properties of small molecules. With a leadership team possessing over a century of combined expertise in the pharmaceutical and biotechnology sectors, the company is uniquely equipped to tackle complex disease indications that have historically proven resistant to conventional pharmacological interventions. Their platform represents a strategic shift toward modular, nature-derived drug design, aiming to provide more effective solutions for patients with high unmet medical needs.
How much funding has Lassogen raised?
Lassogen has raised a total of $4.5M across 1 funding round:
Angel/Seed
$4.5M
Angel/Seed (2020): $4.5M with participation from Playground Global LLC, Foothill Ventures, Better Ventures, and First In Ventures
Key Investors in Lassogen
Better Ventures
Better Ventures is a mission-driven venture capital firm that invests in early-stage startups focusing on leveraging science and technology to create a sustainable economy that benefits people and the planet.
Foothill Ventures
Foothill Ventures is a multi-stage venture firm that partners with technical founders to build companies in the deep tech, life sciences, and software sectors.
Playground Global LLC
Playground Global is a venture capital firm that specializes in backing deep-tech startups, providing both capital and operational support to help founders scale complex engineering and scientific breakthroughs.
What's next for Lassogen?
With this major strategic investment, Lassogen is poised to accelerate its research and development pipeline, transitioning from early-stage discovery toward more robust preclinical validation. The capital will likely be deployed to scale their proprietary platform, optimize the manufacturing processes for Lassotides, and expand their internal team of scientists. As the company matures, the focus will shift toward establishing key partnerships and advancing lead candidates into clinical trials, marking a critical phase in their lifecycle as they seek to validate their therapeutic modality in human subjects and address systemic challenges in the current biotech landscape.
See full Lassogen company page
